PAL.AX WACC - Weighted Average Cost of Capital
The WACC of Palla Pharma Ltd (PAL.AX) is 6.1%.
| Range | Selected | |
| Cost of equity | 6.0% - 8.7% | 7.35% |
| Tax rate | 30.0% - 30.0% | 30% |
| Cost of debt | 4.0% - 4.6% | 4.3% |
| WACC | 5.1% - 7.2% | 6.1% |
| Category | Low | High |
| Long-term bond rate | 4.0% | 4.5% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.38 | 0.61 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.0% | 8.7% |
| Tax rate | 30.0% | 30.0% |
| Debt/Equity ratio | 0.39 | 0.39 |
| Cost of debt | 4.0% | 4.6% |
| After-tax WACC | 5.1% | 7.2% |
| Selected WACC | 6.1% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| PAL.AX | Palla Pharma Ltd | 0.39 | 1.18 | 0.93 |
| 043090.KQ | Cube&Company Co Ltd | 2.66 | -0.63 | -0.22 |
| 087010.KQ | Peptron Inc | 0 | -0.16 | -0.16 |
| 206650.KQ | EuBiologics Co Ltd | 0.03 | 0.16 | 0.15 |
| 215380.KQ | Woojung Bio Inc | 2.13 | 1.38 | 0.55 |
| 238120.KQ | Aligned Genetics Inc | 0.07 | 0.61 | 0.59 |
| BPH.AX | BPH Energy Ltd | 0.01 | 0.18 | 0.18 |
| CTE.AX | Cryosite Ltd | 0.06 | -0.44 | -0.42 |
| GSS.AX | Genetic Signatures Ltd | 0.01 | 0.95 | 0.94 |
| MEM.AX | Memphasys Ltd | 0.4 | -0.11 | -0.09 |
| Low | High | |
| Unlevered beta | 0.06 | 0.33 |
| Relevered beta | 0.07 | 0.42 |
| Adjusted relevered beta | 0.38 | 0.61 |
PAL.AX's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for PAL.AX:
cost_of_equity (7.35%) = risk_free_rate (4.25%) + equity_risk_premium (5.60%) * adjusted_beta (0.38) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.